Patents by Inventor Robert D. Larsen

Robert D. Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11980911
    Abstract: A sprayer includes a spray gun and a hopper. An air source provides compressed air to the sprayer to both eject fluid from the spray gun as a spray and to pressurize the hopper. The spray gun includes passages for providing compressed air to the nozzle for spraying and to the hopper for pressurizing the hopper. The spray gun further includes a relief valve for venting pressurized air from the hopper. The hopper receives the compressed air through a port in the hopper, and the compressed air assists the flow of material out of the hopper and into the spray gun.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: May 14, 2024
    Assignee: Graco Minnesota Inc.
    Inventors: Steven D. Becker, David M. Larsen, Steve J. Wrobel, Mark D. Shultz, Robert J. Gundersen
  • Patent number: 7264485
    Abstract: The present invention relates to electrical connectors, and, in particular, to power connectors and to improved contact structures and methods related thereto.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: September 4, 2007
    Assignee: Winchester Electronics Corporation
    Inventors: Robert D. Larsen, Lee M. Drozdenko
  • Patent number: 7160122
    Abstract: The present invention relates to electrical connectors, and, in particular, to power connectors and to improved contact structures and methods related thereto.
    Type: Grant
    Filed: October 19, 2005
    Date of Patent: January 9, 2007
    Assignee: Winchester Electronics Corporation
    Inventors: Robert D. Larsen, Lee M. Drozdenko
  • Publication number: 20040023977
    Abstract: The present invention relates to a process for preparing substituted thiazolyl-amino pyrimidinyl piperazines, which are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases.
    Type: Application
    Filed: July 14, 2003
    Publication date: February 5, 2004
    Inventors: Robert D. Larsen, Anthony On-Ping King
  • Publication number: 20030134307
    Abstract: This invention provides methods for performing combined asymmetric amplification (e.g., asymmetric PCR amplification) and detection of nucleic acid targets using molecular beacons to detect the products. Methods using a polymerase having reduced or eliminated 5′ to 3′ nuclease activity are provided, as are methods using nuclease-resistant molecular beacons. Asymmetric amplifications using nuclease-free polymerase or nuclease-resistant molecular beacons provide dramatic improvements in signal intensity detected as a result of molecular beacon binding to a target nucleic acid, e.g., during asymmetric PCR. Attendant compositions, systems, devices and kits are also features of the invention.
    Type: Application
    Filed: October 25, 2002
    Publication date: July 17, 2003
    Applicant: Gorilla Genomics, Inc.
    Inventors: Kenneth B. Beckman, Robert D. Larsen, Kathleen Y. Lee
  • Patent number: 6372911
    Abstract: A process for preparing a &bgr;-hydroxy carbamate product is disclosed. The process comprises reacting an olefin compound containing at least one carbon-carbon double bond with a carbamate in an aqueous solvent and in the presence of a base, an osmium catalyst, a co-oxidant selected from a halohydantoin, a haloisocyanuric acid, and an alkali metal salt of a haloisocyanuric acid, and optionally an asymmetric ligand, to form a reaction mixture containing the &bgr;-hydroxy carbamate product. The process optionally further comprises treating the &bgr;-hydroxy carbamate product with additional base to form an oxazolidinone. The oxazolidinones are useful as chiral auxiliary agents and as intermediates for the formation of pharmaceutically active substances such as alpha 1 a adrenergic receptor antagonists. A process for preparing nitrogen-functionalized derivatives of the oxazolidinones is also disclosed.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: April 16, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Nancy Barta, Robert D. Larsen, Daniel R. Sidler, Steven A. Weissman
  • Patent number: 6369275
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: April 9, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 6320049
    Abstract: This invention relates to crystalline pharmaceutically acceptable salts of an alpha 1a adrenergic receptor antagonist, Compound A, which are useful in the treatment of benign prostatic hyperplasia. Pharmaceutical compositions employing the crystalline salts, and processes for making and using the crystalline salts and pharmaceutical compositions of Compound A are also disclosed. This invention further relates to a process for obtaining enantiomerically pure intermediate useful for the synthesis of end product alpha 1a adrenergic receptor antagonists. The end product compounds are useful for the treatment of benign prostatic hyperplasia and for relaxing lower urinary tract tissue. The invention also relates to a process for preparing a class of dihydropyrimidinone compounds of which Compound A is a member, wherein the process involves deprotonating a dihydropyrimidinone compound and then coupling the deprotonated derivative with a primary amine.
    Type: Grant
    Filed: May 2, 2000
    Date of Patent: November 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Daniel R. Sidler, Robert D. Larsen, Wenjie Li
  • Patent number: 6281391
    Abstract: This invention encompasses a novel process for synthesizing compounds represented by formula A: These compounds are intermediates useful in the preparation of certain agents that are selective COX-2 inhibitors.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: August 28, 2001
    Assignees: Merck & Co., Inc., Merck Frosst Canada & Co.
    Inventors: Richard D. Tillyer, Ian W. Davies, Robert D. Larsen, Xin Wang, Paul O'Shea, Anthony On-Ping King, Dalian Zhao, Cheng Y. Chen, Edward J. J. Grabowski
  • Patent number: 6252116
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: June 26, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Edward G. Corley, Ian W. Davies, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 6204387
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: March 23, 2000
    Date of Patent: March 20, 2001
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Linda Gerena, Michel Journet, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 6140515
    Abstract: Described is a process of preparing 3-aryl, 4-aryloxy furan-5-ones which are useful as inhibitors of cyclooxygenase-2 (COX-2). Such compounds are useful as anti-inflammatory agents. The process is directed to an asymmetric synthesis which involves: a trisubstituted styrene derivative preparation via Horner-Wadsworth-Emmons reaction and subsequent one pot trifluoromethylation of the allylic alcohol; preparation of the .alpha.-hydroxyl ketone using Sharpless asymmetric dihydroxylation and Swern oxidation; the esterification of the .alpha.-hydroxyl ketone with the phenoxy acetic acid; and the Dieckman condensation of the resulting ester.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: October 31, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Cheng Y. Chen, Lushi Tan, Robert D. Larsen
  • Patent number: 6127545
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: September 18, 1998
    Date of Patent: October 3, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Philip J. Pye, Kai Rossen, Ashok Maliakal, Ralph P. Volante, Jess Sager, Jean-Francois Marcoux, Ian Davies, Edward G. Corley, Daniel Richard Sidler, Robert D. Larsen
  • Patent number: 6051707
    Abstract: The present invention is concerned with a novel linear process for the preparation of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl) phenyl)-ethoxy)-4-(5-(dimethylamino)methyl-1,2,3-triazol-4-yl)methyl-3-(S) -(4-fluorophenyl)-morpholine which is a potent and selective substance P (or neurokinin-1) receptor antagonist usefull as a therapeutic agent.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Dongwei Cai, Michel Journet, Robert D. Larsen
  • Patent number: 6040450
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: September 15, 1998
    Date of Patent: March 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Ian W. Davies, Michel Journet, Linda Gerena, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 6040319
    Abstract: The invention encompasses a process for making compounds of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: April 23, 1999
    Date of Patent: March 21, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Edward G. Corley, Ian W. Davies, Robert D. Larsen, Philip J. Pye, Kai Rossen
  • Patent number: 5877329
    Abstract: Indoles of structural formula (III): ##STR1## are synthesized by the palladium-catalyzed coupling/ring closure of a 2-halo or 2-trifluoromethylsulfonyloxy aniline and an alkyl ketone derivative. The process is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a facile leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: March 2, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Cheng-Yi Chen, Robert D. Larsen
  • Patent number: 5834502
    Abstract: The bisulfate salt of N,N-dimethyl-2-?5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl!ethylamine is a selective agonist of 5-HT.sub.1 -like receptors and is useful in the treatment of migraine and associated disorders.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: November 10, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Chen Y. Cheng, James A. McCauley, Jennifer L. Vandrilla, Thomas R. Verhoeven, Robert D. Larsen
  • Patent number: 5811551
    Abstract: We have found that indoles of structural formula (III): ##STR1## can be cost-effectively synthesized in high yield by the palladium-catalyzed coupling/ring closure of a 2-halo- or 2-trifluoromethylsulfonyl-aniline and a cyclic ketone derivative. The process of the present invention is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a good leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: September 22, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Cheng-Yi Chen, Robert D. Larsen
  • Patent number: 5808064
    Abstract: We have found that 2-unsubstituted indoles of structural formula (IV) can be cost-effectively synthesized in high yield by the palladium-catalyzed coupling/ring closure of a 2-halo or 2-trifluoromethylsulfonyloxy aniline (I) and an acyl silane derivative (II), followed by deprotection of the silyl protecting groups. ##STR1## The process of the present invention is particularly useful to form indoles containing acid-labile substituents such as triazole, acetyl, ketal, cyano, and carbamate, or indoles having a good leaving group in the benzyl position. The advantages of the present process are that it does not require the use of triphenyl phosphine or tetrabutyl ammonium chloride or lithium chloride. When applied to 5-triazolyl substituted indoles, the present process also eliminates the tendency of triazolyl polymerization in the Fischer indole synthesis.
    Type: Grant
    Filed: August 7, 1997
    Date of Patent: September 15, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Cheng-Yi Chen, Robert D. Larsen